Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - IOVANCE BIOTHERAPEUTICS, INC. | iova-20201231xex32d1.htm |
| EX-31.2 - EX-31.2 - IOVANCE BIOTHERAPEUTICS, INC. | iova-20201231xex31d2.htm |
| EX-31.1 - EX-31.1 - IOVANCE BIOTHERAPEUTICS, INC. | iova-20201231xex31d1.htm |
| EX-23.1 - EX-23.1 - IOVANCE BIOTHERAPEUTICS, INC. | iova-20201231xex23d1.htm |
| EX-21.1 - EX-21.1 - IOVANCE BIOTHERAPEUTICS, INC. | iova-20201231xex21d1.htm |
| EX-10.30 - EX-10.30 - IOVANCE BIOTHERAPEUTICS, INC. | iova-20201231xex10d30.htm |
| 10-K - 10-K - IOVANCE BIOTHERAPEUTICS, INC. | iova-20201231x10k.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
I, Jean-Marc Bellemin, Chief Financial Officer of Iovance Biotherapeutics, Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
· the Annual Report on Form 10-K of the Company for the year ended December 31, 2020 (Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
· the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.
Date: February 25, 2021 | |
| |
| /s/ Jean-Marc Bellemin |
| Jean-Marc Bellemin |
| Chief Financial Officer |
| (Principal Financial Officer) |